The Basel-based multinational, which supplies the pharma industry, expects the CHF500 million ($522 million) facility to be ready in 2026.
The site in Stein, northern Switzerland, will be dedicated to the specialised tasks of filling vials with vaccine and finishing the packaging for distribution (known as fill and finish in the industry). It is a process that is often outsourced in the pharma sector and known to cause bottlenecks in the availability of new vaccines.
“Combined with our strong drug substance manufacturing footprint, the new facility will enable us to provide customers with an integrated end-to-end offering across their entire product life cycle,” said CEO Pierre-Alain Ruffieux on Friday.
The new facility will be more energy efficient and have a photovoltaic roof. It will be built on the same campus as Lonza’s clinical drug product facility in Stein. The company also manufactures drugs in Basel and Visp, as well as in Guangzhou, China.
Pro-Palestine uni protests to be debated in Swiss parliament
This content was published on
The Swiss People’s Party says it will launch two postulates calling for clarifications about the recent student protests and occupations.
This content was published on
A 36-year-old man from Ticino lost his life on Saturday in Val Malvaglia, in the north of canton Ticino, during a wingsuit jump from a plane.
Swiss Evangelical Reformed Church numbers dropping in French-speaking Switzerland
This content was published on
As in German-speaking Switzerland, the number of members of the Reformed Church in French-speaking Switzerland is also declining.
Gotthard traffic queue hits 20km during holiday weekend
This content was published on
The traffic jam at the Gotthard north portal reached a length of 20 kilometres on the motorway between canton Nidwalden and canton Uri.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pandemic reveals Switzerland’s weak spot in securing foreign talent
This content was published on
Switzerland is increasingly being challenged as a business location because of immigration restrictions. Could the pandemic be a turning point?
Lonza to double production of Covid-19 vaccine at Swiss plant
This content was published on
The Swiss firm will add three more production lines to its plant as part of a larger effort to boost Moderna’s global supply of vaccine doses.
Covid vaccines: how to end the wait for billions of people
This content was published on
A waiver on intellectual property rights could be the key to getting more Covid drugs and vaccines to the developing world. But it's controversial.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.